AzTrials
AzTrials

Endometrial CancerNCT07882277

27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery

A study testing 27-Inch Endoscopic Imaging Monitor and 55-Inch Endoscopic Imaging Monitor in people with Endometrial Cancer, run by Metehan Uzundal at 1 site in Turkey (Türkiye).

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Endometrial Cancer
What is being tested?
27-Inch Endoscopic Imaging Monitor and 55-Inch Endoscopic Imaging Monitor
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteTurkey (Türkiye)
Study dates
Oct 2026to Feb 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Female patients aged 18 years or older
  • Histologically diagnosed endometrial cancer with planned surgical treatment
  • Eligible for minimally invasive surgery
  • Planned total laparoscopic hysterectomy with bilateral salpingectomy or bilateral salpingo-oophorectomy and sentinel lymph node dissection
  • No severe systemic disease that would contraindicate laparoscopic surgery based on preoperative evaluation
  • Standard cervical four-quadrant indocyanine green injection planned for sentinel lymph node mapping
Show all 9Show fewer
  • Bilateral sentinel lymph node mapping and bilateral sentinel lymph node dissection feasible during surgery
  • Preoperative hemoglobin level of 10 g/dL or higher
  • Able and willing to provide written informed consent

Who cannot join

  • Distant metastasis detected on preoperative imaging or clinical evaluation
  • Not suitable for minimally invasive surgery, such as severe cardiopulmonary disease
  • Conversion from laparoscopy to laparotomy
  • Failure of bilateral sentinel lymph node mapping or inability to perform bilateral sentinel lymph node dissection
  • Systematic pelvic and/or para-aortic lymph node dissection performed
  • Body mass index of 40 kg/m² or higher
Show all 15Show fewer
  • Uterine size equivalent to 12 weeks of gestation or larger
  • Dense bowel or omental adhesions detected intraoperatively
  • History of abdominal surgery through a midline incision
  • History of myomectomy
  • History of tubo-ovarian abscess
  • History of three or more cesarean deliveries
  • Need for an additional major surgical procedure outside the standardized surgical protocol
  • Preoperative hemoglobin level below 10 g/dL
  • Refusal to participate or inability to provide informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Metehan Uzundal, MD contact

+90 541 291 23 88

metehan_uzndl@hotmail.com

Turkey (Türkiye)1 site

  • Basaksehir Cam and Sakura City Hospital

    Istanbul, Istanbul, 34480

    Metehan Uzundal, MD, +90 541 291 23 88, metehan_uzndl@hotmail.com

    Metehan Uzundal, MD

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of 27-Inch and 55-Inch Endoscopic Imaging Monitors on Surgical and Postoperative Outcomes in Endometrial Cancer Surgery: A Randomized Controlled Trial

This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups. All participants will undergo the same standard surgical procedure; only the monitor size used during surgery will differ. The main question is whether monitor size affects total operative time. The study will also evaluate sentinel lymph node dissection time, blood count changes, complications, infections, hospital stay, and drain-related outcomes during the first 30 days after surgery.

Read the detailed description

This is a single-center, prospective, randomized, parallel-group clinical study designed to evaluate whether endoscopic imaging monitor size affects surgical and early postoperative outcomes in minimally invasive endometrial cancer surgery. Eligible adult women with histologically diagnosed endometrial cancer who are scheduled for total laparoscopic hysterectomy with bilateral salpingectomy or salpingo-oophorectomy and bilateral sentinel lymph node dissection will be enrolled after informed consent.

Participants will be randomly assigned in a 1:1 ratio to surgery using either a 27-inch endoscopic imaging monitor or a 55-inch endoscopic imaging monitor. Both monitor systems are standard surgical imaging equipment used in routine clinical practice. The surgical procedure, operative technique, energy devices, sentinel lymph node mapping approach, and postoperative care will be standardized across both groups. No additional invasive procedure, investigational drug, biologic product, or experimental treatment will be used as part of this study.

The primary outcome measure is total operative time, defined as the time from entry of the laparoscopic optic into the abdomen after trocar placement to completion of surgery. Secondary outcomes include bilateral pelvic sentinel lymph node dissection time, number of right and left sentinel lymph nodes removed, hemoglobin and hematocrit decrease, blood transfusion requirement, intraoperative complications, postoperative complications within 30 days, postoperative infections within 30 days, Clavien-Dindo complication grade, length of hospital stay, drain requirement, and postoperative day of drain removal if a drain is placed.

Participants will be followed during hospitalization and at postoperative day 7-10 and day 30 visits. The study aims to determine whether monitor size has a measurable effect on operative performance and early postoperative outcomes in a standardized minimally invasive surgical setting.

Being tested
27-Inch Endoscopic Imaging Monitor, 55-Inch Endoscopic Imaging Monitor
Keywords
Minimally Invasive Surgery, Laparoscopy, Laparoscopic Hysterectomy, Sentinel Lymph Node Dissection, Endoscopic Imaging Monitor, Monitor Size
Medical subject headings
Endometrial Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 27-Inch Endoscopic Imaging MonitorDevice

    Use of a 27-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.

  • 55-Inch Endoscopic Imaging MonitorDevice

    Use of a 55-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.

Study groups in NCT07882277
Study groupRoleWhat they receive
27-Inch Monitor GroupExperimentalParticipants randomized to this arm will undergo minimally invasive endometrial cancer surgery using a 27-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.
Receives: Device: 27-Inch Endoscopic Imaging Monitor
55-Inch Monitor GroupActive comparatorParticipants randomized to this arm will undergo the same minimally invasive endometrial cancer surgery using a 55-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.
Receives: Device: 55-Inch Endoscopic Imaging Monitor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Operative Time

    Total operative time, defined as the time from entry of the laparoscopic optic into the abdomen after trocar placement to completion of surgery, measured in minutes.

    Measured: During surgery

Secondary outcomes (12)

  1. Bilateral Pelvic Sentinel Lymph Node Dissection Time

    Time required to complete bilateral pelvic sentinel lymph node dissection, measured in minutes.

    Measured: During surgery

  2. Number of Retrieved Sentinel Lymph Nodes

    Number of right and left sentinel lymph nodes removed during surgery.

    Measured: From surgery to final pathology assessment, up to 30 days after surgery

  3. Hemoglobin Decrease

    Percentage decrease in hemoglobin level calculated using preoperative and postoperative 24-hour hemoglobin values.

    Measured: Preoperative to postoperative 24 hours

  4. Hematocrit Decrease

    Percentage decrease in hematocrit level calculated using preoperative and postoperative 24-hour hematocrit values.

    Measured: Preoperative to postoperative 24 hours

  5. Blood Transfusion Requirement

    Need for perioperative or postoperative blood transfusion, recorded as yes or no.

    Measured: From start of surgery to hospital discharge, up to 30 days after surgery

  6. Intraoperative Complications

    Occurrence of any intraoperative complication, recorded as yes or no.

    Measured: During surgery

  7. Postoperative Complications Within 30 Days

    Occurrence of any postoperative complication within 30 days after surgery, recorded as yes or no.

    Measured: Up to 30 days after surgery

  8. Postoperative Infections Within 30 Days

    Occurrence of postoperative infection within 30 days after surgery, recorded as yes or no.

    Measured: Up to 30 days after surgery

  9. Clavien-Dindo Complication Grade

    Severity of postoperative complications classified according to the Clavien-Dindo classification

    Measured: Up to 30 days after surgery

  10. Length of Hospital Stay

    Duration of postoperative hospital stay, measured in days.

    Measured: From surgery to hospital discharge, up to 30 days after surgery

  11. Drain Requirement

    Need for postoperative drain placement, recorded as yes or no.

    Measured: From surgery to hospital discharge, up to 30 days after surgery

  12. Postoperative Day of Drain Removal

    Postoperative day on which the drain is removed in participants with a drain placed

    Measured: From surgery to drain removal, up to 30 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionJan 2028 (estimated)
  4. Study completionFeb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups: surgery using a 27-inch endoscopic imaging monitor or surgery using a 55-inch endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized across both groups.
Masking
Single blind
Who is masked
Participant
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07882277
Sponsor's protocol ID
2024-KAEK-11-255
Status last verified
Oct 2026
First submitted
6 Oct 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared. Study data will be collected and analyzed in a coded and confidential manner, and participant-identifying information will not be disclosed. Results will be reported only in aggregate form.

Publications

  • Walczak DA, Pawelczak D, Piotrowski P, Trzeciak PW, Jedrzejczyk A, Pasieka Z. Video display during laparoscopy - where should it be placed? Wideochir Inne Tech Maloinwazyjne. 2015 Apr;10(1):87-91. doi: 10.5114/wiitm.2014.47434. Epub 2014 Dec 4.

    PubMed 25960798

  • El Shallaly G, Cuschieri A. Optimum view distance for laparoscopic surgery. Surg Endosc. 2006 Dec;20(12):1879-82. doi: 10.1007/s00464-005-0162-1.

    PubMed 17031749

  • Sivas MC, Aslan Cetin B, Ohanoglu Cetinel K, Geyikoglu IE. The effect of using laparoscopic imaging screens of different sizes (55-inch vs. 27-inch) on surgical parameters in hysterectomy surgery: a retrospective cohort study. BMC Surg. 2025 Oct 3;25(1):425. doi: 10.1186/s12893-025-03168-1.

    PubMed 41044554

Questions about this trial

What is this clinical trial studying?

A study testing 27-Inch Endoscopic Imaging Monitor and 55-Inch Endoscopic Imaging Monitor in people with Endometrial Cancer, run by Metehan Uzundal at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Metehan Uzundal, MD (+90 541 291 23 88, metehan_uzndl@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Operative Time (time frame: During surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07882277, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in